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ABSTRACT:
Carbonic anhydrase IX (CAIX) is a hypoxia-inducible enzyme that is overexpressed 
by cancer cells from many tumor types, and is a component of the pH regulatory 
system invoked by these cells to combat the deleterious effects of a high rate of 
glycolytic metabolism. CAIX functions to help produce and maintain an intracellular 
pH (pHi) favorable for tumor cell growth and survival, while at the same time 
participating in the generation of an increasingly acidic extracellular space, 
facilitating tumor cell invasiveness. Pharmacologic interference of CAIX catalytic 
activity using monoclonal antibodies or CAIX-specific small molecule inhibitors, 
consequently disrupting pH regulation by cancer cells, has been shown recently to 
impair primary tumor growth and metastasis. Many of these agents are in preclinical 
or clinical development and constitute a novel, targeted strategy for cancer therapy.
INTRODUCTION
Hypoxia is a salient feature of many types 
of solid cancers and arises as the result of spatial 
disorganization and flow-based disruption of an abnormal 
microvasculature initiated by the growing tumor [1]. The 
impact of tumor hypoxia is multifaceted, with effects 
on several aspects of tumor biology, including genetic 
instability, angiogenesis, invasiveness, survival and 
metabolism [1, 2]. Reduced oxygen availability leads to 
the activation of a core cellular response to hypoxia, the 
master regulators of which are the transcription factors 
hypoxia-inducible factor 1 and 2 (HIF-1/2) [2]. Initiation 
of this core hypoxia-induced signaling cascade results 
in the activation of a vast array of genes, and from these 
arise signaling outputs that regulate a variety of processes 
aimed at adaptation of tumor cells to conditions of low 
oxygen [2]. Amongst the stressors imposed by hypoxia, 
the reduced supply of oxygen limits the capacity for 
oxidative phosphorylation as a means of producing energy 
[3, 4]. Hypoxic, HIF-1α-activated tumor cells respond to 
this microenvironmental stress by reprogramming their 
metabolism to engage the glycoytic pathway, a process 
that is far less efficient, but does not rely on the presence 
of oxygen. This “glycolytic switch” is often permanent 
and persists after reoxygenation, in part because the 
byproducts of glycolysis can be used for anabolic reactions 
that provide a selective advantage to highly proliferative 
tumor cells [3, 4]. The high rate of glycolysis maintained 
by cancer cells is the basis for the Warburg effect [3, 5].
The switch to glycolysis by highly metabolically 
active tumor cells results in increased production and 
export of acidic metabolites, such as lactic and carbonic 
acids, to the extracellular space and leads to a decline in 
extracellular pH (pHe) [6], creating a toxic intratumoral 
microenvironment and providing a selective advantage 
for tumor cells that can survive these harsh conditions. 
One consequence of extracellular acidification is the 
disruption of the intracellular pH (pHi), a decrease in 
which rapidly affects basic cellular functions, including 
membrane integrity, metabolism and energy production, 
and proliferation [4, 6]. Thus, cells must regulate pHi as 
the extracellular pH declines, a process particularly critical 
for tumor cells that prefer a pHi that is somewhat more 
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alkyline compared to that which is optimal for normal 
cells [4, 7]. The combination of an increasingly acidic 
intratumoral microenvironment and a requirement to 
regulate pHi results in the death of non-tumor cells and 
accelerates degradation of the extracellular matrix, thereby 
promoting the invasion and proliferation of acid-resistant 
cancer cells. As such, metabolic alterations induced by 
hypoxia can promote activities associated with aggressive 
tumor cell behavior, including survival, invasion and 
metastasis [8].
The maintenance of pH homeostasis by tumor 
cells relies on a set of complex molecular mechanisms 
involving a variety of proteins and buffer systems with 
the central aim of maintaining a moderately alkaline 
pHi while generating a markedly acidic extracellular 
environment [4, 6]. One set of proteins important to this 
pH regulatory system is the family of carbonic anhydrases 
(CAs) [6, 9]. CAs are a family of 16 distinct, but related 
metalloenzymes whose major enzymatic function is to 
catalyze the reversible hydration of carbon dioxide (CO
2
) 
to bicarbonate (HCO
3
- and protons (H+) (CO
2
 + H
2
O ↔ 
HCO
3
- + H+) [9]. As a group, CAs are important regulators 
of a variety of biological processes, including respiration, 
acid-base regulation, bone resorption and calcification, and 
biosynthetic processes [9]. In the context of tumors, two 
particular isoforms, CAIX and CAXII, are associated with 
cancer progression, metastasis, and impaired therapeutic 
response [4].
CAIX BIOCHEMICAL STRUCTURE
CAIX was initially identified as a membrane-
bound protein on the surface of the HeLa human cervical 
carcinoma cell line and was named the “MN protein” [10, 
11]. However, subsequent analysis of its cDNA sequence 
revealed the presence of a 257 aa long extracellular 
carbonic anhydrase (CA) domain, resulting in the 
acquisition of its current namesake [12, 13]. The recent 
solution of the structure of the catalytic domain of CAIX 
[14] has provided structural confirmation of its observed 
catalytic activity and has aided in more rational drug 
design [15-17]. In contrast to other CA isoforms, CAIX 
is dimeric [17], is among the most active CA for the CO
2
 
hydration reaction [16] and contains a proteoglycan (PG)-
like domain immediately adjacent to the catalytic domain, 
the presence of which may allow the enzyme to function 
most efficiently at more acidic pH values [17, 18]. A single 
pass transmembrane domain separates the extracellular 
portion of CAIX from a short, intracellular tail that is 
involved in regulating its enzymatic activity [19].
REGULATION OF CAIX EXPRESSION
The transcriptional regulation of CAIX has been 
reviewed in detail recently [20] and the discussion here 
is limited its regulation as it pertains to cancer biology. 
Expression of CAIX by tumor cells is generally very 
low in normoxia, but levels are strongly induced during 
hypoxia [21-23]. The CAIX promoter contains a hypoxia 
responsive element (HRE) that is located immediately 
upstream of the transcription start site and that binds 
HIF-1α [21]. Indeed, HIF-1α is the exclusive regulator 
of CAIX activity, in contrast to many hypoxia-induced 
genes, and CAIX is often the most strongly upregulated 
gene in response to hypoxia in human cancer cells [9, 20]. 
Additional transcription factor binding sites present in 
the CAIX promoter appear to coordinate with the HRE to 
promote or amplify the HIF-1 response [20, 24]. 
Importantly, the signaling pathways, soluble factors, 
and microenvironmental conditions that regulate CAIX 
transcription converge on the HIF-1 pathway and CAIX 
expression is coupled directly both to increased protein 
stabilization and transcriptional activity of HIF-1 [20]. 
However, cancer cells grown to high density in vitro 
develop pericellular hypoxia and can upregulate the 
expression of CAIX as a consequence increased HIF-1 
transcriptional activity, but in the absence of detectable 
stabilization of HIF-1, effectively “uncoupling” these 
two arms of HIF-1 regulation [20, 25, 26]. Culturing 
cancer cells at high density also induces signaling 
pathways, including the phosphatidylinositol 3-kinase 
(PI3K) pathway. Under these conditions, PI3K inhibitors 
suppress CAIX expression, revealing that CAIX is driven 
by increased transcriptional activity of HIF-1α resulting 
from mild hypoxia and PI3K activation [25, 27].
While hypoxia is the key driver of CAIX expression 
in cancer cells, there are also data suggesting that 
microenvironmental conditions, tumor suppressors and 
oncogenic signaling pathways may play a role in specific 
circumstances. In studies using glioblastoma cells grown 
in normoxia, acidification of the growth media was 
associated with increased CAIX promoter activity and 
upregulated CAIX expression, and was attributed to 
HIF-1 stabilization and activation of extracellular signal-
regulated kinase (ERK) [28]. However, modulation of pHe 
had no effect on CAIX expression in normoxic HeLa cells 
[29], indicating that pH-driven upregulation of CAIX may 
be cell-type specific. The role of glucose deprivation has 
also been investigated, but results remain inconclusive, 
with some studies reporting heightened expression of 
hypoxia-induced CAIX in response to restricted glucose 
[29], while others have reported reduced CAIX expression 
in these conditions [30]. With regard to tumor suppressors, 
the best characterized example is the role of VHL in 
CAIX upregulation wherein mutation of VHL results in 
constitutive stabilization of HIF-1 in normoxia and drives 
hypoxia-independent expression of HIF-1 regulated genes, 
including CAIX [31]. Indeed, this mechanism results in 
the uniformly high CAIX expression reported in clear cell 
renal cell carcinoma [31]. P53 has also been shown to 
modulate CAIX expression, but again the primary target is 
HIF-1 [32]. Similarly, modulation of CAIX activity by the 
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PI3K pathway and the ERK pathway have been reported, 
but the effects are cell-specific and the modulation of 
CAIX is likely secondary to the modulation of relevant 
transcription factors (HIF-1, SP1/SP3, AP1) [20, 25, 27].
THE ROLE OF CAIX EXPRESSION IN 
NORMAL TISSUE
CAIX expression in normal tissue
CAIX is an especially attractive target for cancer 
therapy, in part because it is overexpressed in a wide 
variety of solid tumors, but is expressed in a limited 
way in normal tissues. Early studies established that the 
differential distribution in cancerous versus normal tissue 
is not the result of mutations [33]. In human tissue, strong 
expression of CAIX is generally limited to the basolateral 
surface of proliferating crypt enterocytes of the duodenum, 
jejunem and ileal mucosa in the human [34]. However, 
diffuse, weak CA IX expression has also been reported in 
the epithelia of human male efferent ducts [35], as well as 
in occasional foci in the pancreatic acini [36]. Analyses 
based on cDNA demonstrated the presence of CA IX 
in gall bladder epithelia [33], but protein has not been 
detected.
In mice, CAIX expression is evident by days 
E11.5-E12.5 [37, 38] and is expressed to significant levels 
in the brain, lung, liver and pancreas, while weak signals 
are evident in the kidney and stomach [38]. Expression 
in the normal adult is restricted to a few tissues, with the 
gastric mucosa exhibiting the highest levels of protein 
[37]. Post transcriptional control of CAIX may be 
evident in some tissues as relatively strong signals were 
observed for CAIX mRNA in the kidney and skeletal 
muscle of Balb/c mice, but these tissues showed little or 
no expression of the protein [37]. Indeed, normal human 
kidney and muscle are essentially null for CAIX mRNA 
and protein [39]. Mice also show expression of CAIX in 
pancreatic acini in a diffusely distributed pattern [37].
Phenotypes in CAIX knock-out animals
As would be predicted from the observations of 
restricted expression of CAIX in normal adult tissues, 
genetic disruption of CAIX expression in mice results in 
mild phenotypes. Global knockout of CAIX in mice by 
targeted gene disruption resulted in homozygous animals 
developing gastric hyperplasia of the glandular epithelium, 
including numerous cysts [40]. The hyperplasia was 
prominent within 4 weeks after birth and loss of CA 
IX expression led to increased numbers of pit cells 
and depletion of pepsinogen-secreting chief cells [40]. 
However, mice developed normally and showed normal 
gastric pH, acid secretion and serum gastrin levels [40]. 
No effect on the hyperplasia and no dysplasia were noted 
when knockout animals were challenged with a high 
salt diet [41], although gastric submucosal inflammation 
was noted in one mouse strain [41]. Importantly, CAIX 
deficiency did not promote tumorgenicity [41], although 
aged CAIX null mice may suffer degenerative disease in 
the brain. At 8 to 10 months of age, vacuolar degenerative 
morphological changes were noted in knockout animals 
[42]. Interestingly, CAIX expression is upregulated about 
2 –fold in mice null for CAII [43], suggesting the presence 
of functional redundancy amongst the CA isozymes.
CAIX EXPRESSION IN TUMOR TISSUE
The discussion above reinforces the fact that 
CAIX expression in the normal adult is highly restricted 
and that interference with its function in normal tissue 
likely has few, if any, significant consequences, except 
perhaps in chronic, age-related situations. On the other 
hand, CAIX is overexpressed in many solid tumors and 
there is now a well-established relationship between 
the expression of CAIX and patient prognosis. CAIX 
expression, as detected by immunohistochemical staining 
of tissue sections, is upregulated and associated with poor 
prognosis in cancers of the lung [44-46], colon [47, 48], 
breast [49-51], cervix [52-55], bladder [56], ovaries [57], 
brain [58], head and neck [59-61], and oral cavity [62, 63]. 
Furthermore, recent studies have examined the expression 
of CAIX in cohorts of hundreds to thousands of patients 
using tissue microarray (TMA) strategies (Table 1). Using 
this high throughput platform, CAIX has been validated 
as a biomarker of poor prognosis in breast [23, 64], lung 
[46], ovarian [57] and bladder cancer [65], as well as in 
astrocytomas [66].
While the vast majority of studies support 
a correlation between CAIX overexpression and 
patient prognosis, a few studies have failed to find a 
relationship. For example, in a TMA study of 99 patients 
that encompassed pre and post (chemo)radiotherapy 
biopsies, CAIX was detected in over 85% of pre-
treatment specimens [67]. However, the study failed to 
find a relationship with prognosis, probably because of 
insufficient numbers of patients [67]. On the other hand, 
in a series of 166 patients with rectal cancer where full 
tissue sections were used, 44% were positive for CAIX 
expression and two thirds of these patients showed 
moderate to strong staining [48]. High CAIX expression 
was indicative of shorter disease-free and disease specific 
survival, and was demonstrated to be an independent 
poor prognostic biomarker [48]. Similarly, most clinical 
studies have demonstrated that a high level of CAIX is a 
biomarker of poor prognosis both in local advanced [52-
55] and in early stage [68, 69] cervical cancer, but some 
studies have failed to find a correlation [70]. 
In addition to overall prognostic information, 
interrogation of TMAs has revealed associations between 
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CAIX overexpression and specific tumor categories. For 
example, CAIX is particularly highly expressed in basal-
like or triple negative breast cancers, a tumor subgroup 
with poor prognosis and known resistance to therapy [23, 
51]. Tumor type dependence has also been reported in 
lung cancer, with a higher percentage of CAIX positive 
tumors amongst the squamous cell phenotype [46]. 
Clinical studies have also revealed a correlation between 
CAIX expression and metastatic disease. Most recently, 
interrogation of over 3600 human breast cancers provided 
definitive evidence of CAIX as an independent biomarker 
of poor prognosis for distant metastases [23]. CAIX 
expression was interrogated in a TMA series of 930 breast 
cancers categorized according to patient survival and 
overexpression was correlated with death and metastatic 
disease [71]. Several studies have now demonstrated that 
CAIX levels are associated with metastasis-free survival 
in multivariate analyses [52-54, 69], and high levels of 
CAIX expression are associated with greater lymph node 
metastases [54, 55].
There is now increasing focus on the use of soluble, 
plasma CAIX for clinical detection and prognostic 
evaluation. Initial studies involving relatively small sample 
sizes showed that soluble, serum CAIX was upregulated 
in patients with solid tumors [72, 73] and could be used 
to detect clinically relevant disease, although prognostic 
impact was not realized. However, recent studies have 
shown an association between soluble CAIX and patient 
prognosis. Preoperative serum CAIX concentrations in 
vulvar cancer correlated with intratumoral expression 
and increased serum CAIX levels were associated with 
poor prognosis [74]. Serum levels of CAIX in metastatic 
breast cancer were also correlated with poor prognosis, as 
well as with the incidence of circulating tumor cells [75]. 
Similarly, in NSCLC, high plasma levels of CAIX were 
associated with significantly shorter overall survival [46].
BIOLOGICAL FUNCTIONS OF CAIX IN 
CANCER CELLS
CAIX and control of tumor pH
The role of CAIX in the control of pH dynamics 
in solid tumors is now well-recognized [6, 76]. 
The maintenance of pH homeostasis by tumor cells 
encompasses several complex molecular mechanisms 
involving a variety of proteins and buffer systems with the 
central aim of maintaining a moderately alkaline pHi while 
generating a markedly acidic extracellular environment 
[6] (Figure 1). Indeed, tumor cells generally favor a 
more alkaline pHi than their normal counterparts [4]. A 
change in the pHi/pHe ratio of 0.1-0.2 pH units can have 
disasterous consequences for critical biological processes 
including ATP synthesis, proliferation, migration, survival 
and metastasis [6, 8]. The primary enzymatic function of 
CAIX is to catalyze the reversible hydration of carbon 
dioxide to bicarbonate and protons (CO
2
 + H
2
O ↔ HCO
3
- 
+ H+). The location of the active site of CAIX on the 
extracellular surface of the plasma membrane positions it 
well for the enzyme to contribute to acidification of the 
tumor microenvironment in hypoxia. In fact, CAIX has 
been said to act as a “catalytic converter” for the excretion 
of acid from cells [77]. Bicarbonate is shuttled into the 
cytoplasm to buffer pHi, while the proton remains in the 
extracellular space. Thus, CAIX has a dual role in the 
growth of hypoxic, CO
2
 excreting tumors (Figure 1). 
First, it helps to produce and maintain an alkyline pHi 
favorable for tumor growth. Second, it participates in the 
generation of an increasingly acidic extracellular space, 
facilitating tumor cell invasiveness [6, 76, 77]. Inhibition 
of CAIX interferes with removal of acid and results in a 
decrease in pHi, negatively influencing cell survival [76, 
77] (Figure 1). Furthermore, low pHe is associated with 
tumorigenic transformation, chromosomal rearrangements, 
extracellular matrix breakdown, migration and invasion, 
Cancer Type 
[citation]
# of Samples Total CAIX +ve (%)
Prognostic Indicator
Univariate Analysis Multivariate Analysis
DSS OS MFS DSS OS MFS
Breast [23] 3630 16 Yes NR Yes Yes Yes Yes
Breast [64] 144 26 NR Yes NR NR Yes NR
NSCLC [46] 555 24 Yes Yes NR Yes NS NR
Ovarian [57] 205 26 NR Yes NR NR Yes NR
Bladder [65] 340 71 NR Yes NR NR Yes NR
Astrocytoma [66] 362 78 NR Yes NR NR Yes NR
DSS, disease specific survival; OS, overall survival; MFS, metastasis free survival; NR, not reported; NS, not significant.
Table 1: Tissue microarray studies evaluating CAIX as a poor prognostic biomarker in human cancer
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protease activation and growth factor production [6, 76]. 
Inhibition of CAIX would also attenuate these processes, 
thereby reducing tumor growth and invasion (Figure 1).
Regulation of CAIX activity
Recent data have suggested that the regions flanking 
the catalytic domain, in particular the PG-like domain 
and the intracellular tail, are critical for modulating the 
catalytic activity of CAIX. The PG-like domain allows 
CAIX to remain highly catalytically active at low pH 
values that would kill most enzymes [17]. Mutagenesis 
of a cluster of basic amino acids in the intracellular tail 
affected the function of the extracellular catalytic domain, 
suggesting that the cytoplasmic tail plays a role in inside-
out signaling [78, 79]. In addition, the intracellular tail 
contains three potential phosphorylation sites, 443T, 448S 
and 449Y. Data suggest that 449Y plays a role in EGF-R-
induced signaling to Akt [80], while cAMP-mediated 
activation of PKA in hypoxia leads to PKA-induced 
phosphorylation on 443T of CAIX, resulting in increased 
activity [19]. Interestingly, full activation of CAIX also 
appears to require dephosphorylation of 448S [19].
CAIX in cell adhesion, migration and proliferation
In addition to its role in the regulation of tumoral 
pH and tumor cell survival, there is evidence that 
CAIX contributes to cell processes such as adhesion 
and migration, both of which are vital for metastatic 
progression in human cancer. In CAIX-null MDCK 
cells constitutively expressing human CAIX, the 
Figure 1: Pharmacologic inhibition of CAIX activity inhibits cancer cell survival and invasion. Hypoxia induces a HIF-
1-mediated signaling cascade that results nuclear translocation of HIF-1α and activation of hypoxia-regulated genes, including GLUT1, 
MCT1/4 and CAIX. Cells reprogram their metabolism to engage the glycoytic pathway, a “glycolytic switch” that results in increased 
production and export of lactate, leading to a decline in pHe. One consequence of extracellular acidification is the disruption of the 
intracellular pH (pHi), a decrease in which rapidly affects basic cellular functions. The overexpression of CAIX in hypoxia catalyzes the 
hydrolysis of CO
2
 to HCO
3
- and H+ in the extracellular microenvironment. The HCO
3
- is actively transported into the cancer cell, thereby 
regulating pHi and maintaining cell survival. The H+ participate in the generation of an increasingly acidic extracellular space, promoting 
tumor cell invasiveness. Inhibition of CAIX catalytic activity using monoclonal antibodies or specific small molecule inhibitors prevent the 
production of these enzymatic metabolites, leading to decreased survival and reduced invasive capacity.
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protein localized to cell-cell junctions and overlapped 
with staining for E-cadherin [81]. Reoxygenation of 
hypoxia-cultured cells resulted in delocalization of CA 
IX and E-cadherin from the membrane to the cytoplasm, 
followed by relocalization to the membrane upon return 
to hypoxia [81]. CAIX-expressing MDCK cells showed 
lower cell adhesion and CA IX immunoprecipitated 
with β-catenin in these cells, suggesting that CAIX 
may modulate E-cadherin-mediated cell adhesion by 
competing with E-cadherin for binding to β-catenin 
[81]. Gene expression analysis of cervical carcinoma 
cells overexpressing exogenous human CAIX revealed 
differential regulation of genes involved in cell growth, 
cell adhesion and cytoskeletal organization [82]. These 
cells showed weakened cell-cell adhesion and increased 
cell motility. Moreover, constitutive CAIX expression 
induced inactivation of Rho and led to EMT in these cells 
[82]. The expression of CAIX may also be involved in 
cell proliferation. Several studies have also reported a 
reduction in proliferation when CAIX is inhibited, at 
least in cells exogeneously overexpressing CAIX [83-85]. 
Together, these studies suggest that inhibition of CAIX in 
hypoxic tumors may have anti-tumor effects that extend 
beyond control of intratumoral pH.
PHARMACOLOGIC INHIBITION OF 
CAIX AS A MEANS OF THERAPEUTIC 
INTERVENTION IN CANCER
CAIX is an attractive target for anticancer therapy 
for several reasons. It is selectively expressed by tumor 
cells and shows highly restricted expression in normal 
tissue. It provides functions critical for tumor growth 
and metastasis, including pH regulation, survival and 
adhesion/migration. It is positioned on the extracellular 
surface of cell membranes, allowing efficient targeting 
by antibodies or small molecule inhibitors. Furthermore, 
genetic silencing of CAIX in preclinical tumor models in 
vivo has demonstrated the requirement of CAIX for the 
growth of hypoxic tumors and their metastasis. Genetic 
depletion of CAIX, together with CAXII, in LS147Tr 
colorectal cancer xenografts resulted in an 85% reduction 
in tumor growth [86]. Silencing of CAIX expression in 
4T1 mouse metastatic breast cancer cells resulted in 
regression of orthotopic mammary tumors and inhibition 
of spontaneous lung metastasis formation [23]. Stable 
depletion of CAIX in MDA-MB-231 human breast cancer 
xenografts also resulted in attenuation of primary tumor 
growth [23]. These studies provide proof of principle data 
showing that inhibition of CAIX is of potential therapeutic 
benefit. Two major tools that are being investigated for 
their efficacy as CAIX-specific therapeutic modalities in 
cancer treatment are monoclonal antibodies and small 
molecule inhibitors.
Monoclonal antibodies
Immunotherapy using CAIX-specific monoclonal 
antibodies (mAbs) may derive its therapeutic efficacy 
through a variety of mechanisms. Direct binding of 
the mAb to CAIX can elicit an anti-tumor response 
due to antibody-mediated cell cytotoxicity (ADCC). 
Alternatively, receptor-mediated internalization allows 
for targeted delivery of various therapeutic  payloads, 
including cytotoxins and radionuclides. Furthermore, 
development of mAbs targeting the CAIX active site 
provides potential for selective blocking of CAIX 
function.
Historically, two mAbs, M75 [10] and G250 [87], 
have dominated as CAIX-specific immunological tools 
for clinical detection and/or therapy. M75 is a highly-
specific antibody targeting the PG-like domain of CAIX 
and it is used widely for immunohistochemical detection 
of CAIX in human tumor tissue [79]. A radiolabeled 
derivative has been developed for imaging CAIX in 
hypoxic tumors preclinically [88, 89], but M75 has not 
been developed for application as an immunotherapy. In 
contrast, a chimeric version of G250, cG250, has been 
developed and extensively characterized as an anticancer 
immunotherapy [90]. Early studies showed that cG250 
could elicit antibody-dependent cellular cytotoxicity 
(ADCC) [91], an established mechanism by which 
therapeutic mAbs mediate tumor cell destruction. Phase 
I and II trials demonstrated that this Ab was safe, well-
tolerated and able to positively impact disease burden, 
alone and together with interferon (IFN)-α treatment [92, 
93]. cG250 is currently marketed by WILEX AG under 
the trade name RENCAREX® and phase III trials have 
now been initiated using cG250 as an adjuvant therapy 
aimed at reducing recurrence in surgically-treated renal 
cell carcinoma (RCC) patients who have a high risk of 
relapse and in combination with interleukin 2 (IL-2) or 
IFN-α for metastatic RCC [4, 79, 92].
While M75 and cG250 are directed at the PG-
like domain of CAIX, recent studies have focused on 
developing antibodies targeted against its catalytic 
domain. These antibodies have the advantage of 
specifically disrupting the catalytic activity of the enzyme, 
thus targeting its tumorigenic functions, including pH 
regulation. High throughput screening technologies, 
especially the use of phage display libraries [94-96], have 
been employed to efficiently identify CAIX antibodies. 
Epitopes of some of the fragments have mapped to the 
catalytic site, and these have been shown to inhibit CAIX 
activity in vitro [94, 96]. Inhibition of CAIX in spheroid 
cell cultures has also been demonstrated, suggesting that 
these mAbs could be used to inhibit CAIX therapeutically 
[94]. However, in vivo experiments demonstrating efficacy 
as anti-tumor agents have not been performed. Two mAbs 
generated by phage display and with high affinity to 
CAIX have been shown to bind CAIX in tumors in vivo 
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[95], but again, evaluation of anti-tumor efficacy was not 
performed. On the other hand, a mAb directed against the 
CAIX catalytic domain and generated using hybridoma 
technology has been developed and tested in vivo [79]. 
The mAb showed efficient binding, internalization and 
persistence in cultured cells. In vivo evaluation in HT-
29 colorectal xenografts demonstrated that treatment 
immediately after cell inoculation effectively limited 
tumor growth, but the effect was very modest when tumors 
were allowed to establish prior to treatment [79]. 
While selective inhibition of CAIX catalytic 
activity by mAbs exploits the property of mAbs to not 
spontaneously cross the plasma membrane, the utility 
of mAbs in cancer therapy is often driven by their 
ability to undergo receptor-mediated internalization. Ab 
internalization is required for delivery of therapeutic 
payloads, including radionuclides and cytotoxic drugs, and 
CAIX Abs have been developed to exploit this property. 
For example, a portion of the cG250 Ab is internalized, 
and metallic radionuclides, including 177Lu and 90Y, have 
been introduced into cellular lysosomes using cG250 in 
mice, producing a therapeutic growth delay in xenograft 
tumors [97]. A phase I/II trial in metastatic RCC patients is 
currently ongoing [98]. In a very recent study a CAIX mAb 
identified from a phage display library was conjugated to 
monomethyl auristatin E (MMAE) and the efficacy of 
this Ab-drug conjugate (BAY79-4620) was evaluated in 
several preclinical human xenograft tumor models [99]. 
Drug delivery to target cells involved internalization of 
the mAb and anti-tumor efficacy correlated with CAIX 
expression, with tumors showing the most robust levels of 
CAIX expression also having the best therapeutic response 
[99].
CAIX-specific small molecule inhibitors
Several broad classes of small molecules are 
known to effectively inhibit CAs [4, 9], and compounds 
based on sulfonamide/sulfamates and coumarins have 
demonstrated particular promise as potential anti cancer 
agents. Interestingly, these two inhibitor classes are 
mechanistically distinct in their inhibition of CAs. The 
sulfonamides inhibit CAIX by coordinating to the zinc ion 
within the active site, while molecules based on coumarin/
thiocoumarin act as suicide inhibitors, undergoing 
hydrolysis to 2-hydroxycinnamic acids and binding 
irreversibly at the entrance to the active site cavity [100, 
101]. 
Evaluation of CAIX inhibitors in cell culture
The high degree of homology amongst the catalytic 
sites of the various mammalian CAs has presented a 
challenge to the design and development of isozyme-
specific agents. The development of compounds that 
selectively inhibit tumor associated, extracellular CAs 
without “off-target” inhibition of intracellular CAs such 
as CAII is critical for their use as cancer therapeutics 
[4, 9]. Several strategies have evolved to “dial in” the 
selectivity of small molecule inhibitors of CAIX, such 
as the addition of charges species, bulky entities such 
as FITC or albumin or hydrophilic sugar moieties, all of 
which limit transport across the plasma membrane [4, 9]. 
Tumor Model [citation] Inhibitor Effect
LS174T human colon carcinoma [109] fluoro-acetazolamide bound to xenograft tissue; no significant effect 
on tumor growth
SK-RC-52 human renal cell carcinoma [109] albumin-acetazolamide significant reduction in tumor growth
HT-29 human renal cell carcinoma [110] bis sulfonamide tumor-specific accumulation; effect on tumor 
growth not measured
HT-29 human renal cell carcinoma [111] fluorescent sulfonamide tumor-specific accumulation; effect on tumor 
growth not measured
4T1 metastatic mouse breast cancer [23] fluorescent sulfonamide significant inhibition of tumor growth
4T1 metastatic mouse breast cancer [23, 102] ureido sulfonamides inhibition of experimental lung metastases
4T1 metastatic mouse breast cancer [23, 103] glycosyl coumarins inhibition of experimental lung metastases; 
inhibition of primary tumor growth
MDA-MB-231 LM2-4 lung metastatic breast 
cancer [23]
ureido sulfonamides inhibition of primary tumor growth
HT-29 human renal cell carcinoma [84] indanesulfonamide inhibition of primary tumor growth; synergy 
with radiotherapy
Table 2: Targeting of CAIX by small molecules in preclinical models of human cancer
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Other approaches include the use of distinct chemotypes of 
sulfonamides [102] or coumarins [103] that are inherently 
selective for extracellular CAs such as CAIX. Many of 
these compounds have been evaluated as both potent 
and selective for CAIX based on in vitro assays using 
recombinant CAs. In some studies, efficient attenuation of 
cell growth by a series of chemically defined CA inhibitors 
has been demonstrated using panels of cultured tumor 
cell lines representing a variety of types of cancers [104, 
105]. While these studies have identified CA inhibitors as 
potential anti-cancer therapeutics, the experiments were 
performed in normoxia without analysis of CAIX status, 
thus evaluation of the specific role of CAIX on tumor cell 
viability was not possible. Indeed, these studies suggest 
that some of these CA inhibitors may work effectively 
as cytotoxic agents in cancer therapy [104, 105]. Ideally, 
inhibitors that specifically target CAIX-overexpressing 
cancer cells while exhibiting no effects on normal, CAIX-
negative cells would be desired.
A growing number of selective CAIX inhibitors 
have been evaluated in cell culture models and have 
provided evidence both of their CAIX-specific nature 
and their potential as anti-tumor agents. To date, the best 
characterized CAIX-selective small molecule inhibitor 
is a FITC-labeled fluorescent sulfonamide [9]. This 
compound has a high affinity for extracellular CAs. Cell 
culture studies using both MDCK cells that overexpress 
CAIX and human tumor cell lines that constitutively 
express CAIX or induce the enzyme in hypoxia have 
demonstrated that this inhibitor binds only to active 
CAIX in hypoxia [23, 106] and inhibits CAIX-mediated 
acidification of the extracellular environment [23, 106, 
107]. Interestingly, similar data was reported recently 
for a fluorescently labeled sulfamate [84]. The influence 
of CAIX inhibitors on cancer cell viability has also been 
investigated. Human renal carcinoma cell lines with or 
without constitutive expression of CAIX, together with 
cell density dependent upregulation of CAIX in HeLa 
cells, were used as models to test the functional impact of 
two aromatic sulfonamides, TR1 and GA15 [83]. Results 
showed that these inhibitors preferentially reduced pHi 
and proliferation, and induced apoptosis and ceramide 
production in CAIX-positive cells, but not in CAIX-
negative cells [83]. Treatment with an indanesulfonamide 
CAIX inhibitor in HT-29 human colon carcinoma cells 
resulted in reduced proliferation and increased apoptosis, 
but did not affect intrinsic radiosensitivity in this cell line 
[84]. Such studies demonstrate that sulfonamide inhibitors 
can be engineered to bind selectively to CAIX and inhibit 
its biological functions in cell culture. Interestingly, some 
of these experiments were carried out in normoxia [83], 
suggesting that certain CAIX inhibitors may function 
regardless of hypoxia-induced activation. Thus, these 
inhibitors can negatively impact cancer cell viability in a 
CAIX-dependent manner.
Evaluation of selective CAIX inhibitors in 
preclinical models
Despite great scientific interest in CAIX as a 
biomarker, imaging target and therapeutic target for 
hypoxic tumors, preclinical evaluation of targeted agents 
remains in its infancy. The paucity of appropriate, CAIX-
positive preclinical models and the complexities involved 
in synthesizing small molecule inhibitors that are highly 
selective for the CAIX isozyme remain as challenges 
in the field [4, 23, 108]. Recently, however, progress 
has been made in developing small molecule inhibitors 
with reasonable selectivity for extracellular CAIX that 
demonstrate efficacy in vivo (Table 2). 
Initial attempts to target CAIX therapeutically in 
vivo used inhibitors based on acetazolamide, onto which 
albumin binding moieties or charged flurophores were 
attached, thereby restricting the binding of acetazolamide 
to extracellular CAs [109]. The fluorophore-conjugated 
inhibitor bound to LS174T human colon carcinoma 
xenograft tissue in a pattern similar to that seen with 
antibodies against CAIX, but a decrease in tumor growth 
was not observed in this model [109]. However, treatment 
of SK-RC-52 human renal cell carcinoma xenografts 
constitutively expressing CAIX with the albumin-binding 
variant did produce a significant decrease in tumor growth 
[109]. The inhibitor was also effective when used in 
combination with sunitinib, although the combination 
treatment did not significantly outperform sunitinib alone 
[109], likely because of the high efficacy of sunitinib in 
this tumor model. More recently, one of several potent bis-
sulfonamide CAIX inhibitors identified in a screen of 1 
million compounds in a DNA-encoded chemical library 
was found to exhibit strong tumor-specific accumulation 
in these tumor models [110]. Tumor-specific, oxygen-
dependent localization of the established fluorescent 
sulfonamide inhibitor of CAIX in HT-29 colon carcinoma 
xenografts has also been reported [111]. While tumor 
growth inhibition per se was not measured in these studies, 
the results indicate the ability of highly selective CAIX 
inhibitors to bind specifically to their target in vivo.
Recent studies have now demonstrated that 
CAIX-selective sulfonamide inhibitors can directly and 
specifically inhibit the growth of hypoxic, CAIX-positive 
tumors in preclinical animal models. Treatment of hypoxic, 
metastatic 4T1 mouse breast tumors in an orthotopic 
setting with an established fluorescent sulfonamide CAIX 
inhibitor resulted in significant inhibition of tumor growth, 
whereas similar treatment of primary tumors derived 
from non-metastatic 67NR cells did not have an effect on 
tumor growth [23]. Furthermore, delivery of novel ureido 
sulfonamide [102] and glycosyl coumarin [103] inhibitors 
of CAIX into human and mouse models of orthotopic, 
CAIX-positive breast cancer resulted in significant 
inhibition of primary tumor growth. An anti-tumor effect 
has also been demonstrated recently by inhibiting CAIX 
Oncotarget 2012; 3:  84 - 9792www.impactjournals.com/oncotarget
using an indanesulfonamide [84]. Interestingly, treatment 
of HT-29 xenografts with this high affinity inhibitor 
of CAIX resulted in reduced tumor growth, and further 
regression what observed when the inhibitor was used in 
combination with radiotherapy [84]. Collectively, these 
studies provide strong preclinical evidence for the use of 
CAIX inhibitors as targeted pharmacologic agents for the 
treatment of hypoxic, aggressive solid cancers.
In addition to their effects on the growth of hypoxic 
primary tumors, recent data suggest that sulfonamide and 
coumarin inhibitors of CAIX activity are efficacious in 
reducing metastatic burden in preclinical models of cancer. 
In two separate studies, treatment of experimental models 
of breast cancer metastasis with novel ureido sulfonamides 
has resulted in a significant decrease in lung metastases 
[23, 102]. Similar results have been achieved using novel 
glycosyl coumarins [23, 103], suggesting that this new 
generation of selective CAIX inhibitors have the capacity 
to work as targeted therapeutics for both the treatment 
of primary tumors and metastatic progression, at least in 
breast cancer.
CONCLUSION AND PERSPECTIVES
As solid malignancies progress, they often become 
hypoxic, triggering a core, HIF-1-mediated signaling 
cascade that results in the activation of a plethora of genes 
vital for the adaptation of tumor cells to an increasingly 
stressful environment. As part of this response, tumor cells 
undergo a glycolyic switch that enables them to continue 
to grow in conditions of low oxygen. As a consequence 
of this altered metabolism, acidic metabolites are released 
into the extracellular environment, lowering the pHe and 
putting pressure on tumor cells to maintain their pHi. 
Therefore, cancer cells become increasingly reliant on a 
multi-component pH regulatory system for their continued 
survival and invasive behavior, and interference with one 
or more effectors of this system can prove detrimental to 
tumor growth.
CAIX is a hypoxia-inducible component of the 
tumoral pH regulatory system. Its upregulation results in 
dramatically enhanced hydrolysis of CO
2
 to HCO
3
- and 
H+ at the extracellular surface of cancer cells, providing 
a chemical buffer that is actively transported into the cell 
to help maintain pHi and a source of H+ that contributes 
to the increasing acidosis of the extracellular space. As 
discussed here, it is now well-recognized that CAIX is 
highly overexpressed in several solid cancer types, in 
sharp contrast to the restricted expression of this protein 
in normal tissues, making it a clinically relevant target for 
novel cancer therapeutics.
Preclinical and clinical evaluation of novel CAIX-
selective therapies have, until recently, been slowed by 
the lack of availability of appropriate animal models 
and the development of chemical compounds that 
selectively inhibit tumor associated, extracellular CAs 
without “off-target” inhibition of intracellular CAs. 
However, several CAIX-targeted therapeutic agents, 
including monoclonal antibodies and small molecule 
inhibitors, have been developed recently. Today, selective 
monoclonal antibody therapies have entered clinical 
trials and several additional antibody-based modalities 
show promise in experimental models. Importantly, 
inhibition of CAIX with sulfonamide- or coumarin-
based inhibitors is efficacious in reducing tumor growth 
and inhibiting metastasis in preclinical tumor models 
without the compromising effects of non-specific toxicity. 
These attributes suggest that such inhibitors are likely 
to be useful clinically, especially if administered in 
combination with conventional chemotherapy. Indeed, 
the use of nontoxic targeted therapies in combination 
with conventional anticancer drugs or radiotherapy is the 
current clinical paradigm, and the inhibition of CAIX in 
this context may yield even better efficacy.
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